PET imaging of hypoxia using [18F]HX4: A phase i trial

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 9, 2010, Pages 1663-1668

  Van Loon, Judith ^a   Janssen, Marco H M ^a   Öllers, Michel ^a   Aerts, Hugo J W L ^a   Dubois, Ludwig ^a   Hochstenbag, Monique ^b   Dingemans, Anne Marie C ^b   Lalisang, Roy ^b   Brans, Boudewijn ^b   Windhorst, Bert ^c   Van Dongen, Guus A ^c   Kolb, Hartmuth ^d   Zhang, James ^d   De Ruysscher, Dirk ^a   Lambin, Philippe ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Siemens Molecular Imaging   (United States)

Author keywords

2 Nitroimidazoles; 18F HX4; Hypoxia; PET; Phase I trial

Indexed keywords

2 [4 [(2 NITRO 1H IMIDAZOL 1 YL)METHYL] 1H 1,2,3 TRIAZOL 1 YL]PROPAN 1 OL FLUORINE F 18; 2 NITROIMIDAZOLE DERIVATIVE; FLUORINE 18; HX 4; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CARCINOMA; DRUG DOSE COMPARISON; FEMALE; HUMAN; HYPOXIA; IMAGE QUALITY; LUNG NON SMALL CELL CANCER; MALE; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; SINGLE DRUG DOSE; SOLID TUMOR; THYMUS CANCER;

AGED; CELL HYPOXIA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEOPLASMS; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY; TIME FACTORS; TRIAZOLES;

EID: 77956187952     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-010-1437-x     Document Type: Article

References (10)

1. K Ruan G Song G Ouyang 2009 Role of hypoxia in the hallmarks of human cancer J Cell Biochem 107 1053 1062 10.1002/jcb.22214 1:CAS:528: DC%2BD1MXptlOnuro%3D 19479945
2. BG Wouters SA Weppler M Koritzinsky W Landuyt S Nuyts J Theys, et al. 2002 Hypoxia as a target for combined modality treatments Eur J Cancer 38 240 257 10.1016/S0959-8049(01)00361-6 1:STN:280:DC%2BD38%2Fns1Omtw%3D%3D 11803141
3. JS Rasey Z Grunbaum S Magee NJ Nelson PL Olive RE Durand, et al. 1987 Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells Radiat Res 111 292 304 10.2307/3576986 1:CAS:528:DyaL2sXlslWmt70%3D 3628717
4. D Thorwarth SM Eschmann F Paulsen M Alber 2005 A kinetic model for dynamic [18F]-Fmiso PET data to analyse tumour hypoxia Phys Med Biol 50 2209 2224 10.1088/0031-9155/50/10/002 15876662
5. A Nunn K Linder HW Strauss 1995 Nitroimidazoles and imaging hypoxia Eur J Nucl Med 22 265 280 10.1007/BF01081524 1:CAS:528:DyaK2MXlsFygt7g%3D 7789400
6. KA Krohn JM Link RP Mason 2008 Molecular imaging of hypoxia J Nucl Med 49 Suppl 2 129S 148S 10.2967/jnumed.107.045914 1:CAS:528:DC%2BD1cXotFahu78%3D 18523070
7. M Piert HJ Machulla M Picchio G Reischl S Ziegler P Kumar, et al. 2005 Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside J Nucl Med 46 106 113 15632040
8. M Ollers G Bosmans A van Baardwijk A Dekker P Lambin J Teule, et al. 2008 The integration of PET-CT scans from different hospitals into radiotherapy treatment planning Radiother Oncol 87 142 146 10.1016/j.radonc.2007.12.025 18207269
9. RA Dierckx C Van de Wiele 2008 FDG uptake, a surrogate of tumour hypoxia? Eur J Nucl Med Mol Imaging 35 1544 1549 10.1007/s00259-008-0758-5 1:CAS:528:DC%2BD1cXovFyqtbY%3D 18509637
10. A van Baardwijk C Dooms RJ van Suylen E Verbeken M Hochstenbag C Dehing-Oberije, et al. 2007 The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer Eur J Cancer 43 1392 1398 10.1016/j.ejca.2007.03.027 17512190